Skip to main content

Novavax

Novavax Inc is an American biotechnology company specializing in recombinant protein nanoparticle vaccines and adjuvants for infectious diseases. The company develops, manufactures, and markets protein-based vaccines, including its Matrix-M-adjuvanted COVID-19 vaccine and combination respiratory vaccine candidates. Main revenue drivers include commercial vaccine product sales, licensing agreements, and government vaccine development grants. Novavax serves public health agencies, healthcare providers, pharmacy networks, and international procurement organizations across North America, Europe, and Asia. The company holds a prominent market position as a developer of protein-based vaccine technology and adjuvant systems. Headquartered in Gaithersburg, Maryland, Novavax Inc is listed on the Nasdaq Stock Market.

3 of the funds FundTelligence covers report a position in Novavax.

Legal name
NOVAVAX
Sector
Health Care
Country
United States
Funds holding it
3

Funds holding Novavax

Loading...